google-site-verification: googlec7193c3de77668c9.html

Masked T‑cell engagers: Cancer immunotherapies for the future?

[
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a “masked T-cell engager.” This type of immunotherapy ignites our own immune arsenal to fight cancer.


Source link

Advertisements
Views: 4

See also  MIND diet significantly reduces dementia risk, new research shows

Check Also

Blood biomarkers could detect earliest signs of Alzheimer's disease—and slow its progression

[ Alzheimer’s disease, a progressive neurodegenerative disorder that affects millions worldwide, has a long preclinical …

Ebola toll tops 200, other African countries seen at risk

[ Officials in the Democratic Republic of Congo updated the death toll from the Ebola …

Common epilepsy drug disrupts early brain growth in human organoids after 30-day exposure

[ Brain research in a Petri dish: Organoids can be used to study disease processes. …

Leave a Reply

Available for Amazon Prime